Skeletal Morbidity Rates over Time in Patients with Bone Metastases from Solid Tumors Reported in Bone Modifying Agents Randomised Trials

Overview

Journal J Bone Oncol

Publisher Elsevier

Date 2016 Feb 25

PMID 26909260

Authors

Michael Poon

Liang Zeng

Liying Zhang

Marko Popovic

Ronald Chow

Henry Lam

Gillian Bedard

Urban Emmenegger

Christine Simmons

Edward Chow

Affiliations

Soon will be listed here.

Abstract

Objective: Skeletal related events (SREs) are common in patients with bone metastases and lead to decreased quality of life and functional status. The definition of an SRE has evolved over the years and now excludes hypercalcemia of malignancy due to its low incidence. The purpose of this review was to investigate if advances in bone-targeted therapies have decreased skeletal morbidity rates (SMR) over time.

Methods: A literature search was conducted in several databases to identify phase III results from bone-targeted therapy trials from 1980 through September 2011. Graphs were created to document the trends of the natural log of SMR over the mean time of enrolment for all placebo and intervention arms. Statistical hypothesis testing was employed to account for confounding factors.

Results: A total of 14 studies were identified which reported the SMR from phase III trials from 1990 to 2007. A statistically significant downward trend was observed in the placebo arms of trials over time; a similar trend was seen in all intervention arms. In a direct comparison of intervention against placebo arms, it was found that there was a significant decreasing time trend (p<0.0001) and a significant departure in SMR from placebo to intervention arms (p=0.0348). These results were seen even after accounting for the confounding factors of histology and differences in drugs.

Conclusion: The decrease in SMR over time may not only be a result of advancements with bone targeted agents, but also due to better management and awareness of events associated with bone metastases.

References

Dearnaley D, Sydes M, Mason M, Stott M, Powell C, Robinson A . A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003; 95(17):1300-11. DOI: 10.1093/jnci/djg038. View

Body J, Diel I, Lichinitser M, Kreuser E, Dornoff W, Gorbunova V . Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003; 14(9):1399-405. DOI: 10.1093/annonc/mdg367. View

Rosen L, Gordon D, Tchekmedyian N, Yanagihara R, Hirsh V, Krzakowski M . Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100(12):2613-21. DOI: 10.1002/cncr.20308. View

Rosen L, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M . Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21(16):3150-7. DOI: 10.1200/JCO.2003.04.105. View

Rosen L, Gordon D, Dugan Jr W, Major P, Eisenberg P, Provencher L . Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2003; 100(1):36-43. DOI: 10.1002/cncr.11892. View

Shiue K, Sahgal A, Chow E, Lutz S, Chang E, Mayr N . Management of metastatic spinal cord compression. Expert Rev Anticancer Ther. 2010; 10(5):697-708. DOI: 10.1586/era.10.47. View

Theriault R, Lipton A, Hortobagyi G, Leff R, Gluck S, Stewart J . Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999; 17(3):846-54. DOI: 10.1200/JCO.1999.17.3.846. View

Higginson I, Finlay I, Goodwin D, Cook A, Hood K, Edwards A . Do hospital-based palliative teams improve care for patients or families at the end of life?. J Pain Symptom Manage. 2002; 23(2):96-106. DOI: 10.1016/s0885-3924(01)00406-7. View

Polascik T . Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther. 2009; 3:27-40. PMC: 2769231. View

10.

Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J . The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2005; 67(5-6):390-6. DOI: 10.1159/000082923. View

11.

Saad F, Eastham J . Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology. 2010; 76(5):1175-81. DOI: 10.1016/j.urology.2010.05.026. View

12.

Saad F, Chen Y, Gleason D, Chin J . Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007; 5(6):390-6. DOI: 10.3816/CGC.2007.n.022. View

13.

Lipton A, Zheng M, Seaman J . Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003; 98(5):962-9. DOI: 10.1002/cncr.11571. View

14.

Saad F, Lipton A . Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2006; 97(6):1351-2. DOI: 10.1111/j.1464-410X.2006.06279_7.x. View

15.

Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View

16.

Ristevski B, Jenkinson R, Stephen D, Finkelstein J, Schemitsch E, McKee M . Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg. 2009; 52(4):302-308. PMC: 2724796. View

17.

Lagman R, Walsh D . Integration of palliative medicine into comprehensive cancer care. Semin Oncol. 2005; 32(2):134-8. DOI: 10.1053/j.seminoncol.2004.11.015. View

18.

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

19.

Lipton A, Theriault R, Hortobagyi G, Simeone J, Knight R, Mellars K . Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88(5):1082-90. DOI: 10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z. View

20.

Langer C, Hirsh V . Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer. 2009; 67(1):4-11. DOI: 10.1016/j.lungcan.2009.08.020. View